Income Taxes	3 Months Ended
Dec. 31, 2013
Income Taxes
Income Taxes	3. Income Taxes The income tax expense for the three months ended December 31, 2013 was approximately $416,000 compared to approximately $96,000 for the three months ended December 31, 2012. The effective tax rate for the three months ended December 31, 2013 was 29%. The effective tax rate differs from the statutory rate for the three months ended December 31, 2013, primarily because of the Domestic Production Activities Deduction, and the federal Research and Development Tax Credit (“R&D Tax Credit”). The effective tax rate for the three months ended December 31, 2012 was 23%. The effective tax rate differs from the statutory rate for the three months ended December 31, 2012, primarily because of the decrease in the liability recorded for uncertain tax positions resulting from the lapse of applicable statutes of limitation and the Domestic Production Activities Deduction. On January 2, 2013, the American Taxpayer Relief Act of 2012 (the “Tax Relief Act”) was enacted, which retroactively reinstated and extended the R&D Tax Credit from January 1, 2012 to December 31, 2013. The current year estimated annual effective income tax rate reflects the benefit from the Federal R&D Tax Credit for only the three months ended December 31, 2013 as permitted by ASC Topic 740, because the R&D Tax Credit expired as of December 31, 2013. At December 31, 2013, the balance of the deferred tax valuation allowance relates principally to NOLs of certain state taxing jurisdictions. The Company will continue to maintain the balance of the valuation allowance until the Company generates a sufficient level of profitability in certain jurisdictions to warrant a conclusion that it is no longer more likely than not that these net state deferred tax assets will not be realized in future periods. There is currently no assurance of such future income before taxes. The Company believes that its estimate of future taxable income is inherently uncertain, and therefore, further adjustments to the valuation allowance are possible.

Income Taxes

3 Months Ended

Dec. 31, 2013

3. Income Taxes

The income tax expense for the three months ended December 31, 2013 was approximately $416,000 compared to approximately $96,000 for the three months ended December 31, 2012.

The effective tax rate for the three months ended December 31, 2013 was 29%. The effective tax rate differs from the statutory rate for the three months ended December 31, 2013, primarily because of the Domestic Production Activities Deduction, and the federal Research and Development Tax Credit (“R&D Tax Credit”).

The effective tax rate for the three months ended December 31, 2012 was 23%. The effective tax rate differs from the statutory rate for the three months ended December 31, 2012, primarily because of the decrease in the liability recorded for uncertain tax positions resulting from the lapse of applicable statutes of limitation and the Domestic Production Activities Deduction.

On January 2, 2013, the American Taxpayer Relief Act of 2012 (the “Tax Relief Act”) was enacted, which retroactively reinstated and extended the R&D Tax Credit from January 1, 2012 to December 31, 2013. The current year estimated annual effective income tax rate reflects the benefit from the Federal R&D Tax Credit for only the three months ended December 31, 2013 as permitted by ASC Topic 740, because the R&D Tax Credit expired as of December 31, 2013.

At December 31, 2013, the balance of the deferred tax valuation allowance relates principally to NOLs of certain state taxing jurisdictions. The Company will continue to maintain the balance of the valuation allowance until the Company generates a sufficient level of profitability in certain jurisdictions to warrant a conclusion that it is no longer more likely than not that these net state deferred tax assets will not be realized in future periods. There is currently no assurance of such future income before taxes. The Company believes that its estimate of future taxable income is inherently uncertain, and therefore, further adjustments to the valuation allowance are possible.